Hepatopathy is a prominent feature of mitochondrial depletion syndrome (MDS) caused by mutations in the nuclear genes encoding proteins responsible for mtDNA maintenance, replication, or nucleotide substrate delivery (*POLG*, *DGUOK*, and *MPV17*) (Dimmock et al. [@CR4]). Since 1991, an increasing number of MDS has been reported among neonates, infants, and children who died due to progressive liver failure (Müller-Höcker et al. [@CR11]; Rabinowitz et al. [@CR15]). The disease is characterized by tissue-specific pathology, generally unusual for mitochondrial disorders.

Deoxyguanosine kinase deficiency (dGK) associated with mutations in the deoxyguanosine kinase (*DGUOK*) gene was uncovered as a genetic background of hepatic MDS phenotype by Mandel et al. in 2001 (Mandel et al. [@CR10]). Since then, more than 50 patients from 35 affected families have been reported (Salviati et al. [@CR17]; Mancuso et al. [@CR9]; Filosto et al. [@CR5]; Labarthe et al. [@CR8]; Slama et al. [@CR21]; Wang et al. [@CR25]; Freisinger et al. [@CR6]; Sarzi et al. [@CR18]; Brahimi et al. [@CR3]; Spinazzola et al. [@CR22]). The *DGUOK* gene mutations are considered to be the most common genetic background of hepatic MDS, being responsible for 14--20% of all mtDNA depletion cases (Salviati et al. [@CR17]). Mitochondrial involvement in dGK-deficient patients is evidenced by lactic acidemia and impaired function of the respiratory chain (Mandel et al. [@CR10]). Normal complex II activity (encoded by the nuclear genes) is a specific feature of MDS (Hargreaves et al. [@CR7]).

Twenty-eight infants and children, who died due to progressive liver failure, were recruited for post mortem *DGUOK* gene mutations search. In all patients, a mitochondrial disease had been diagnosed before death. Two of them were included in the COX deficiency cohort described earlier (Böhm et al. [@CR2]). The Bioethical Commission of the Children's Memorial Health Institute (CMHI) approved the study protocol.

Total DNA, extracted from skeletal muscle and liver samples, was used as a template to amplify seven coding exons of the *DGUOK* gene. A set of primers corresponding to each exon and splicing regions of *DGUOK* was used as described previously (Mandel et al. [@CR10]).

The polymerase chain reaction (PCR) conditions were as follows: initial denaturation at 94°C for 2 min followed by 35 cycles at 94°C for 30 s, 62°C for 30 s, 72°C for 30 s, and a final extension step at 72°C for 7 min. Single-stranded DNA products were subjected to exonuclease I digestion and shrimp alkaline phosphatase hydrolysis (Exo-SAP-IT), according to the manufacturer's protocol (USB Corp.), and subsequently sequenced. Sequencing reaction products were purified using DyeEx Kits prior to separation on an ABI 3730 Genetic Analyzer. The gathered data were analyzed using the Chromas Lite 2.01 software.

Sequence analysis revealed the presence of three known pathogenic mutations, c.3G\>A (p.Met1Ile), c.494A\>G (p.Glu165Val), and c.766_767insGATT (p.Phe256X), and one new molecular variant of unknown pathogeneity, c.813_814insTTT (p.Asn271_Thr272insPhe), in the *DGUOK* gene. There were two homozygotes, one compound heterozygote, and one affected patient with mutation found on only one chromosome.

The most frequent mutation identified in our study was the c.3G\>A substitution in the *DGUOK* exon 1, potentially causing a severe impairment in the synthesis of the protein. It was found in two of our patients (in homozygous or heterozygous status, respectively) and it was reported previously only once, also in a patient of Polish origin (Freisinger et al. [@CR6]).

The second mutation, revealed on only one allele in this study, was the frameshift 4-bp insertion in the *DGUOK* exon 6 (c.766_767insGATT). Since 2002, it has been reported in eight unrelated dGK-deficient patients from different regions of the world, especially from Arabian countries and Spain (Wang et al. [@CR25]). The change is considered to be the most frequent and it was suggested to be either an ancient or a recurrent mutation (Salviati et al. [@CR17]; Filosto et al. [@CR5]; Labarthe et al. [@CR8]).

The third known mutation located in exon 4 of the *DGUOK* gene (c.494A\>G) was found in our group in homozygous form in a child of seemingly unrelated parents. The change was reported in 2005 in one heterozygous French patient (Slama et al. [@CR21]; Poulton et al. [@CR14]).

The fourth change was not reported previously (c.813_814insTTT) and its pathogeneity requires further confirmation. Profound mitochondrial DNA depletion confirmed the diagnosis of MDS in this patient. The depletion was also found in all available tissue specimens, in the liver of the patients 1, 2, and 4 (4%, 15%, and 10% of the normal value, respectively), and in all of the patients' muscles (4%, 23%, 45%, and 6%, respectively) (Węglewska et al. [@CR27]; Węglewska-Jurkiewicz [@CR26]).

The course of the disease in our four dGK-deficient patients resembled strikingly clinical features described in the literature (Mandel et al. [@CR10]; Slama et al. [@CR21]; Labarthe et al. [@CR8]; Freisinger et al. [@CR6]). Since remarkable difficulties in differential diagnosis were observed, an expended metabolic testing was required. A number of unusual or "strange" biochemical parameters (see Table [1](#Tab1){ref-type="table"}) directed investigations to various different metabolic pathways. More than ten genetic disorders (including tyrosinemia neonatal or type I, homocystnuria, 2-CH~3~-3-hydroxybutyric aciduria, galactosemia, hereditary fructose intolerance, cytrulinemia type II, biotinidase deficiency, Wilson disease, and lysosomal storage disorders) were suspected and subsequently excluded during the long-term hospitalizations in our referral metabolic center. The diagnosis of a mitochondrial disease was finally established in all four patients on the basis of the association of the lactic acidosis, neurological involvement (relatively mild), and cytochrome C oxidase deficiency (or combined oxidative phosphorylation \[OXPHOS\] defect) found in the muscle biopsy (not shown). Table 1Clinical characteristics and laboratory findings of the four patients with deoxyguanosine kinase (*DGUOK*) gene mutationsPatientCourse of the disease; neurological assessmentSpecific biochemical abnormalitiesDNA changeProtein changePatient 1 girlTwo miscarriages. Low birth weight (2,570 g); 1 d: hypoglycemia; 2 d: hypotonia, vomiting, trembling; then: hepatopathy, hypoglycemia; 15 mo: progression of hepatic dysfunction to end-stage liver failure and death (18 mo)NBS: ↑ methionine; 6 mo: GC-MS: ↑ 2-CH~3~-3-OH-butyric acid, 3-methylglutaconic acid; slightly ↑ lactic acid, p-OH phenylpyruvic acid derivatives; CDT slightly ↑ (14.0 %); ↑ CSF lactate; muscle biopsy: COX deficiencyc.766_767insGATT/c.?p.Phe256X/p.?Neurological status: nystagmus, generalized hypotonia, psychomotor retardationAFP 9700, 31000; Fe 55 TIBC 322 (sat 17%)Patient 2 girlFetus hypotrophy (29 Hbd); caesarean section due to fetus asphyxia (hbd 35, 1,859 g); 1 d: hypotonia, weakness, feeding difficulties, vomiting; 4 d: hepatopathy, hypoglycemia (26 mg/dl). Since 2.5 mo: progression of liver failure, ascites, severe coagulopathy, cholestasis; died at the age of 6.5 moNBS: ↑ tyrosine; GC-MS: ↑ lactic acid, p-OH phenylpyruvic acid derivatives; ↑ galactose excretion in urine; ↑ plasma citrine; ↑ plasma lactatec.3G\>A/c.813_814insTTTp.Met1Ile/Neurological status: hypotonia, psychomotor retardation.AFP 14500, 18500, 33500; Fe 25 TIBC 100 (sat 25%)p.Asn271_Thr272insPhePatient 3 girlLow birth weight (2,640 g); 1 d: severe hypoglycemia, hypotonia, tachypnoea, hypothermia, hepatomegaly, metabolic acidosis, hypertransaminasemia; 6 mo: progression of liver failure, coagulopathy, ascites; deathNBS: abnormal amino acids pattern. ↑ CK (586 -- 207 iU) at neonatal period: GC-MS: ↑↑ lactic acid; p-OH phenylpyruvic acid derivatives ↓serum ceruloplasmin (9 mg/dl) and Cu (36 mg/dl); normal urinary Cu excretion. Muscle biopsy: deficient COX, low compl Ic.3G\>A/c.3G\>Ap.Met1Ile/p.Met1IleNeurological status: hypotonia, psychomotor retardationAFP 9700, 31000; ferritin 287, Fe 138 TIBC 184 (sat 75%)Patient 4 boyLow birth weight (2,350 g); 1 d: generalized hypotonia, weakness, hypoventilation, limbs edema, hypoglycemia (10 mg/dl). Then: progressive liver dysfunction (cholestasis, jaundice, coagulopathy, ascites); 10 wks: death due to end-stage liver failureExpended NBS ND; GC-MS: slightly ↑ lactic acid; p-OH phenylpyruvic acid derivatives. Reducing substances in urine -- positive; ↑ homocysteine; ↓ serum biotinidase activity; ↑ plasma and CSF lactate. Muscle biopsy: deficient COX, low compl Ic.494A\>T/c.494A\>Tp.Glu165Val/p.Glu165ValNeurological status: hypotonia, psychomotor retardationAFP 75000; ferritin 1146 Fe 121 TIBC 139 (sat 87%)NBS, newborn screening; CK, creatine kinase; Cu, copper; CDT, carbohydrate-deficient transferrin (test for congenital glycosylation disorder); GC-MS, gas chromatography--mass spectrometry method for assessment of the urinary profile of organic acids; COX, cytochrome C oxidase; compl, complex of the respiratory chain; AFP, alpha-fetoprotein (normal \< 5 IU); Fe, iron (normal 37--145 μg/dl); TIBC, total iron binding capacity (normal 228--428 μg/dl); transferrin saturation normal value \<30%; ferritin normal value 20--200 ng/dl; d, day(s); wks, weeks; mo, months; CSF, cerebrospinal fluid; ND, not determined

Liver histopathology showed, generally, two distinct patterns of damage. Patients 1 and 3 presented a similar model of parenchymal injury accompanied by bridging fibrosis leading to micronodular transformation and cirrhosis. This picture suggested at least some drive for hepatocytic regeneration. Patients 2 and 4 showed total loss of the liver architecture with diffuse fibrosis, neocholangiole proliferation, and no tendency for cirrhotic nodular transformation, as was shown earlier (Müller-Höcker et al. [@CR11]; Mancuso et al. [@CR9]; Rabinowitz et al. [@CR15]; Labarthe et al. [@CR8]). Focal remnants of the liver parenchyma were either necrotic or severely changed, suggesting early profound hepatocyte injury with subsequent domination of stromal and neocholangiolar reaction. Pancreatic islet cell hyperplasia with numerous confluent giant islets was found in both autopsied infants.

Generally, macro- and microscopic changes reported in the dGK deficiency (Filosto et al. [@CR5]) were not found in the brain of our two autopsied patients. However, insufficient material from accurately identifiable sites to exclude the milder neuropathological features typical for mitochondrial depletion syndromes was available.

A retrospective analysis of the clinical course of the disease in our patients and the literature data led us to summarize some important common observations. Firstly, a relatively low birth weight (\<10th percentile), intrauterine growth retardation (IUGR), or prematurity was observed not only in our dGK-deficient patients but was also mentioned in 14 out of 19 values reported previously. The detection of mtDNA depletion in one affected fetus described additionally confirms a prenatal onset of the disease (Müller-Höcker et al. [@CR11]).

Secondly, our observations suggest, for the first time, that an islet cell hyperplasia found at autopsy of two of our patients may contribute to hypoglycemia in dGK deficiency. Episodes of low glucose concentrations, lasting from the disease onset to the end-stage period, in all of our patients were observed. The hypoglycemia is regularly reported in the hepatic form of MDS, including dGK deficiency, but the impaired homeostasis background was not investigated. We clearly showed in our two patients that it depends on a relative hyperinsulinism (Fig. [1](#Fig1){ref-type="fig"}). The fasting test reveled the typical metabolic profile of low ketone and beta-hydroxybutyrate (BOB) production, relatively high insulin with lower free fatty acids (FFA) release, and increase of hyperglycemic hormones secretion (hGH, glucagon, cortisol) during hypoglycemia. Brisk response to intravenous glucagon injection (and the pancreatic autopsy findings mentioned above) seems to confirm the hypothesis. Fig. 1Parameters of glucose homeostasis in two patients with deoxyguanosine kinase (*DGUOK*) gene mutations during fasting hypoglycemia and after intravenous glucagon loading. *BOB* serum beta-hydroxybutyrate (ketobutyrate) level; *FFA* serum free fatty acids level

The influence of hypoglycemia on the severity of liver dysfunction in the circumstances of mitochondrial energy shortage in MDS may be especially important. Recently, an improvement of the liver function on continuous intravenous glucose infusions and regular feeding was reported in the patients with *MPV17* gene mutation (Parini et al. [@CR12]). Our patients received systematically glucose infusions also, although the correlation between progression of the liver failure and the current glucose supply status was not possible to assess ex post.

Finally, some laboratory features of iron overload were revealed in our affected patients (Siafakas et al. [@CR20]; Ponka [@CR13]). Neonatal hemochromatosis was suspected initially in two of the patients and it was excluded by the pathological examination of the skin and the liver (not shown). However, significant abnormalities in the iron metabolism and transport were suggested by elevated transferrin saturation, relatively low total iron binding capacity (TIBC), and/or increased ferritin level (see Table [1](#Tab1){ref-type="table"}). Theoretically, an excess of free iron ions may have deleterious toxic influence on the liver and subsequent organ damage (Visapää et al. [@CR23]; Ramm and Ruddell [@CR16]). An impaired function of the mitochondria associated with dGK deficiency may still aggravate the process. Decreased hepatic ATP content and reduced activity of the cytochrome C oxidase was observed in an experimental model of iron overload (Bacon et al. [@CR1]). In one report describing a child with iron storage disease, a severe depletion of mtDNA (to 9% of the normal value) was mentioned (Vu et al. [@CR24]).

Interestingly, in our cohort, serum alpha-fetoprotein (AFP) elevation was constantly revealed (Table [1](#Tab1){ref-type="table"}). On the dGK discovery, Mandel et al. rated serum AFP increase as being among the major biochemical findings (Mandel et al. [@CR10]). Only a few other reports mentioned AFP levels (Rabinowitz et al. [@CR15]), which ranged from \<2 ng/ml in an affected neonate to above 85,000 ng/ml or more in other reported cases. The high serum AFP associated with liver malignancy was described by Freisinger et al. in two dGK-deficient patients (Freisinger et al. [@CR6]). Hepatic carcinoma (HCC) was not found in our patients by either liver ultrasound nor during autopsy. It cannot be excluded that the mechanism of the hyper-alpha-fetoproteinemia in dGK is connected with the liver regeneration process (like in tyrosinemia type I), and that, further, dGK-deficient patients will develop HCC if they survive for longer without transplantation (Scheers et al. [@CR19]; Freisinger et al. [@CR6]).

In our experience, an early appropriate identification of the mitochondrial pathology by the investigation of skeletal muscle biopsy (apparently not impaired) may prevent unnecessary escalation of the diagnostic procedures leading to misdiagnoses and inadequate treatment.

A better understanding of the primary or secondary factors influencing liver damage in MDS (including hypoglycemia and iron overload) may contribute to the improvement of the short- and long-term prognosis in children with the hepatic form of this mitochondrial disorder.
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